Several inhibitors for the hepatitis C virus (HCV) NS3/4A protease are under development. Although previous studies identified viral resistance mutations, there is little information on the natural variability of proteases from the different viral subtypes. Here, we aimed to determine both the natural variability and presence of resistance or compensatory mutations to new protease inhibitors (PI) in NS3/4A proteases from worldwide HCV isolates.
Methods
A comprehensive analysis was performed in 380 HCV NS3 sequences (275 genotype 1; 105 other genotypes) from public HCV databases (EuHCVdb and Los Alamos). Amino acid polymorphism and signature patterns were deduced in the protease domain, including all sites associated with resistance to the PIs BILN-2061, Telaprevir (VX-950), Boceprevir (SCH-503034), SCH-6 and ITMN-191.
Results
Few of the residues in the catalytic triad or in substrate/metal-binding sites were polymorphic, and were identified in only 4/380 isolates. However, a relevant polymorphism was found in sites associated either with resistance to PI (V36, I170 and D168) or with compensatory mutations (I71, T72, Q86 and I153). Furthermore, some unique genotype-specific signature patterns associated with resistance to PI were also identified.
Conclusions
We describe for the first time the relevant natural polymorphisms of the HCV NS3/4A protease in worldwide isolates. Although the prevalence of major resistance mutations is very low, many compensatory sites are naturally polymorphic among proteases from several HCV subtypes. These data will help to determine whether HCV resistance is likely to be selected with new PIs and will aid the design of genotypic resistance testing.
HoofnagleJ.H.Course and outcome of hepatitis C.Hepatology2002; 36: s21–s29.
3.
BerenguerM., López-LabradorF.X., WrightT.L.Hepatitis C and liver transplantation.J Hepatol2001; 35: 666–678.
4.
MoradpourD., PeninF., RiceC.M.Replication of hepatitis C virus.Nat Rev Micro2007; 5: 453–463.
5.
SimmondsP.Genetic diversity and evolution of hepatitis C virus – 15 years on.J Gen Virol2004; 85: 3173–3188.
6.
GrakouiA., McCourtD.W., WychowskiC., FeinstoneS.M., RiceC.M.Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.J Virol1993; 67: 2832–2843.
7.
LamarreD., AndersonP.C., BaileyM.An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.Nature2003; 426: 186–189.
8.
HinrichsenH., BenhamouY., WedemeyerH.Short-term antiviral efficacy of BILN-2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.Gastroenterology2004; 127: 1347–1355.
9.
LinK., PerniR.B., KwongA.D., LinC.VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells.Antimicrob Agents Chemother2006; 50: 1813–1822.
10.
LawitzE., Rodriguez-TorresM., MuirA.J.28 Days of the hepatitis C protease inhibitor VX-950, in combination with PEG-interferon-α-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects.Gastroenterology2006; 131: 950–951.
11.
MalcolmB.A., LiuR., LahserF.SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.Antimicrob Agents Chemother2006; 50: 1013–1020.
12.
BogenS.L., ArasappanA., BennettF.Discovery of SCH446211 (SCH-6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.J Med Chem2006; 49: 2750–2757.
13.
LiuR., AbidK., PichardoJ., PazienzaV.In vitro antiviral activity of SCH446211 (SCH-6), a novel inhibitor of the hepatitis C virus NS3 serine protease.J Antimicrob Chemother2007; 59: 51–58.
14.
ProngayA.J., GuoZ., YaoN.Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.J Med Chem2007; 50: 2310–2318.
15.
SeiwertS.D., AndrewsS.W., TanH.Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development.J Hepatol2006; 44: S278.
16.
LinK., KwongA.D., LinC.Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.Antimicrob Agents Chemother2004; 48: 4784–4792.
17.
McHutchisonJ.G.28 Days of the hepatitis C protease inhibitor VX-950, in combination with PEG-interferon-α-2a and Ribavirin, is well-tolerated and demonstrates robust antiviral effects.Gastroenterology2006; 131: 250. Abstract DDW 2006.
18.
SarrazinC., RouzierR., WagnerF.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.Gastroenterology2007; 132: 1270–1278.
19.
FoyE., LiK., WangC.Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.Science2003; 300: 1145–1148.
20.
LiK., FoyE., FerreonJ.C.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.Proc Natl Acad Sci U S A2005; 102: 2992–2997.
21.
CondraJ.H., SchleifW.A., BlahyO.M.In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.Nature1995; 374: 569–571.
22.
TrozziC., BartholomewL., CeccacciA.In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.J Virol2003; 77: 3669–3679.
23.
LuL., Pilot-MatiasT.J., StewartK.D.Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.Antimicrob Agents Chemother2004; 48: 2260–2266.
24.
LinC., LinK., LuongY.P.In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN-2061: structural analysis indicates different resistance mechanisms.J Biol Chem2004; 279: 17508–17514.
25.
LinC., GatesC.A., RaoB.G.In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN-2061.J Biol Chem2005; 280: 36784–36791.
26.
MoH., LuL., Pilot-MatiasT.Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.Antimicrob Agents Chemother2005; 49: 4305–4314.
27.
YiM., TongX., SkeltonA.Mutations conferring resistance to SCH-6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations.J Biol Chem2006; 281: 8205–8215.
ZhouY., MuhU., HanzelkaB.L.Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.J Biol Chem2007; 282: 22619–22628.
30.
ZeuzemS., SarrazinC., WagnerF.The HCV NS3 protease inhibitor SCH 503034 in combination with Peg-IFN alpha-2b in the treatment of HCV-1 Peg-IFN alpha-2b nonresponders: antiviral activity and HCV variant analysis.J Hepatology2006; 44: S35.
31.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Gastroenterology2007; 132: 1767–1777.
32.
ThibeaultD., BousquetC., GingrasR.Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN-2061 10.1128/JVI.78.14.7352-7359.2004.J Virol2004; 78: 7352–7359.
33.
ReiserM., HinrichsenH., BenhamouY.Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.Hepatology2005; 41: 832–835.
34.
Holland-StaleyC.A., KovariL.C., GolenbergE.M., PoburskyK.J., MayersD.L.Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.Arch Virol2002; 147: 1385–1406.
35.
LodriniS., BagaglioS., CanducciF.Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.J Biol Regul Homeost Agents2003; 17: 198–204.
36.
ValletS., GouriouS., NousbaumJ.B., Legrand-QuillienM.C., GoudeauA., PicardB.Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.J Med Virol2005; 75: 528–537.
37.
López-LabradorF.X., BrachoM.A., BerenguerM.Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation.J Viral Hepat2006; 13: 104–115.
38.
SimmondsP., BukhJ., CombetC.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.Hepatology2005; 42: 962–973.
39.
ThompsonJ.D., HigginsD.G., GibsonT.J.CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.Nucleic Acids Res1994; 22: 4673–4680.
HallT.A.Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. In Nucleic Acids Symposium Series1999; 41: 95–98.
42.
XiaX., XieZ.DAMBE: software package for data analysis in molecular biology and evolution.J Hered2001; 92: 371–373.
43.
CrooksG.E., HonG., ChandoniaJ.M., BrennerS.E.WebLogo: a sequence logo generator.Genome Res2004; 14: 1188–1190.
44.
KorberB., MyersG.Signature pattern analysis: a method for assessing viral sequence relatedness.AIDS Res Hum Retroviruses1992; 8: 1549–1560.
45.
TongX., ChaseR., SkeltonA., ChenT., Wright-MinogueJ., MalcolmB.A.Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.Antiviral Res2006; 70: 28–38.
46.
SeiwertS.D., HonJ., LimS.R., WangT., TanH., BlattL.M.Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those lilkely to be achieved following clinical dosing.J Hepatol2007; 46: S244–S245.
47.
FilocamoG., PaciniL., NardiC.Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric Sindbis viruses.J Virol1999; 73: 561–575.
48.
BeyerB.M., ZhangR., HongZ., MadisonV., MalcolmB.A.Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity.Proteins2001; 43: 82–88.
49.
TongX., GuoZ., Wright-MinogueJ.Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.Biochemistry2006; 45: 1353–1361.
50.
van MaarseveenN.M., WensingA.M.J., JongD.Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.J Infect Dis2007; 195: 399–409.
51.
WintersM.A., WellesS.L., HolodniyM.Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.J Virol2006; 80: 4196–4199.
52.
FrancoS., PareraM., AparicioE., ClotetB., MartínezM.A.Genetic and catalytic efficiency structure of an HCV protease quasispecies.Hepatology2007; 45: 899–910.
53.
CombetC., GarnierN., CharavayC.euHCVdb: the European hepatitis C virus database.Nucleic Acids Res2007; 35: D363–366.
54.
HraberP.T., LeachR.W., ReillyL.P., ThurmondJ., YusimK., KuikenC.Los Alamos hepatitis C virus sequence and human immunology databases: an expanding resource for antiviral research.Antivir Chem Chemother2007; 18: 113–123.
55.
KiefferT.L., SarrazinC., MillerJ.S.Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.Hepatology2007; 43: 631–639.
56.
AbeK., IkedaM., DansakoH., NakaK., KatoN.Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA.Virus Res2007; 125: 88–97.
